Review
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy

https://doi.org/10.1016/j.euroneuro.2011.10.003Get rights and content

Abstract

In the last decade the serotonin transporter gene promoter polymorphism (5-HTTLPR) was likely the most studied genetic variant as predictor of antidepressant response. Nevertheless results are not consistent across studies and previous meta-analysis, since various factors seem to modulate its effect on antidepressant response.

With the aim of clarifying this issue, we systematically reviewed literature, selecting 33 studies for an exploratory analysis without any a priori hypothesis. Then we analyzed separately 19 studies performed on Caucasians and 11 on Asians. We tested two phenotypes – remission and response rates – and three genotype comparisons – ll versus ls/ss, ss versus ll/ls and ll versus ss – using the Cochrane review manager. Evaluations were performed separately for SSRIs and mixed/other drugs. Possible clinical modulators were investigated.

In the exploratory analysis, we found an association between l allele and l/l genotype and remission. When the analysis was split for ethnic group, in Caucasians we found an association between l allele and both response (OR = 1.58, C.I. 1.16–2.16, p = 0.004), and remission (OR = 1.53, C.I. 1.14–2.04, p = 0.004) in the SSRI group. Only a marginal association between l allele and remission (OR = 1.41, C.I. 1.02–1.95, p = 0.04) survived pooling together mixed antidepressant treatments. In Asians, a small effect of 5-HTTLPR on remission for mixed antidepressants was detected (OR = 2.10, C.I. 1.15–3.84, p = 0.02). Gender, age and age at onset modulated the association in Caucasians. Gender, age and depression severity at baseline modulated the association in Asians.

In conclusion, in Caucasians 5-HTTLPR may be a predictor of antidepressant response and remission, while in Asians it does not appear to play a major role.

Introduction

Nowadays depression has still an enormous economic burden due to both direct and indirect costs, in the order of tens of billions of dollars each year in the US alone (Halfin, 2007, Wang et al., 2003). Several factors are responsible of this economic burden. Among the most relevant ones, there are the still unsatisfactory rates of response and remission (Machado et al., 2006, Papakostas et al., 2006) (47 and 33%, respectively, in the STAR*D cohort) (Trivedi et al., 2006). Furthermore, initial side effects and failure to perceive benefit are common reasons of early discontinuation (Masand, 2003). The detection of factors that could predict response and minimize side effects of treatments therefore remains an essential goal. Clinical factors have been extensively investigated, but results are still controversial and cannot be translated into the clinical practice (Papakostas et al., 2008, Serretti et al., 2009). On the other hand, several lines of evidence suggested that genetic factors contribute for about 50% of the antidepressant response (Angst, 1965, Franchini et al., 1998, Kirchheiner et al., 2004, Maier and Zobel, 2008, Serretti et al., 1998), although so far the inconsistency of results has not allowed clinical applications.

Despite this discouraging scenario, some polymorphisms were repeatedly associated to antidepressant response, particularly a polymorphism within the promoter of the serotonin transporter gene (SLC6A4), i.e. the 5-HTTLPR. It is a 44 bp insertion/deletion involving two units in a sequence of sixteen repeated elements and possibly influences serotonin transporter (SERT) expression, with the long (l) allele associated with a twice basal expression compared to the short (s) allele (Heils et al., 1996). 5-HTTLPR is a priori excellent candidate for genetic studies, since SERT is one of the main targets for antidepressant drugs and the primary target for SSRIs. Furthermore, it has been associated with several psychiatric disorders with affective symptomatology (i.e. bipolar disorder, anxiety disorders, eating disorders, substance abuse) and to pathological behaviors and personality traits related to anxiety, impulsivity and stress (Serretti et al., 2006). Concerning antidepressant pharmacogenetics, increasing evidence suggest that in Caucasian l allele is associated with better response, although negative findings have been reported as well (Table 1). On the other hand, in Asians an association between s allele and better response was initially reported, though several following studies reported no associations while only few studies found an association with l allele or l/l genotype (see Table 1 and our previous meta-analysis (Serretti et al., 2007b)). So far other ethnicities have not been investigated enough to reach any conclusion. These contradictory findings between Caucasian and other populations may be due to several reasons. Firstly, l allele is much less frequent in Asian compared to Western populations. Indeed: 1. the l/l genotype is present in 29–43% of Caucasians, but in 1–13% of East Asians (Goldman et al., 2010); 2. the s allele is present in 42% of Caucasians, but in 79% of Asians (Kunugi et al., 1997); 3. the s/s genotype varied from 21.6 to 28.3% in the studies including mainly Caucasian patients, while in studies on Asian patients these frequencies varied between 55.6 and 60.0% (Smits et al., 2004). Thus, the low frequency of l allele and l/l genotype in Asians weakens the association between them and response found by some authors. Secondly, other genetic variants within the SERT gene or other related gene may represent further stratification factors. Indeed, a second polymorphism identified within the l allele (rs25531A/G) may determinate a reduced expression of the gene (lG allele), comparable with the expression due to the s allele (Hu et al., 2006). In the light of this finding all the studies performed before the detection of this mutation should be carefully re-examined and future investigations should provide a better covering of the gene (Dong et al., 2009). Finally some recent findings suggested possible interactions between 5-HTTLPR genotype and drug plasma concentration (Lotrich et al., 2008), augmentation strategies (Benedetti et al., 2008, Stamm et al., 2008), life events (Mandelli et al., 2009a) and gender (Walderhaug et al., 2007).

Taken together, these data underline the need for further investigations in order to reach any definitive conclusion. Our previous meta-analysis exploring the association between 5-HTTLPR and antidepressant response, reported positive correlations between l allele and l/l genotype and both response and remission (Serretti et al., 2007b). Despite these results, the increasing amount of data about the topic, especially after the publication of STAR*D results, may be useful to further clarify the role of this relevant polymorphism. These considerations leaded to a new meta-analysis on 5-HTTLPR and antidepressant response. Conversely to our findings, authors did not find any association between 5-HTTLPR and both antidepressant response and remission (Taylor et al., 2010). Nevertheless, they did not perform separate meta-analyses on the basis of the ethnicity that, as stated above, is a well-known confounding factor in pharmacogenetic studies. The confounding role of ethnicity seems even more relevant for 5-HTTLPR, since the very different frequencies of its alleles among different populations (see above) and the increasing evidence of a different effect of 5-HTTLPR in Caucasian and Asian populations (Table 1). As a matter of fact, also Taylor and colleagues observed that ethnicity may be a stratifying factor, thus they included it as moderator in their meta-regression, finding a negative result. Despite this, the limited statistical power of meta-regression approach (Baker et al., 2009) and the previously reported considerations suggest the need of further analysis to clarify this issue. Therefore the aim of the present paper was to perform a meta-analysis on the association between 5-HTTLPR and antidepressant response, firstly considering available studies until November 2010 both on Caucasian and Asian samples to perform an exploratory analysis without any a priori hypothesis. We then tried to dissect the obtained results by separated analysis in Caucasian and Asian populations, in order to reach a relatively definitive conclusion on the role of 5-HTTLPR on the antidepressant response in both the populations in exam. Despite the recent evidence of possible influence exerted by other polymorphisms within SLC6A4promoter, we focus this meta-analysis on the biallelic insertion/deletion polymorphism; indeed, it is the most known and studied so far, while data about the role of the other polymorphisms within the region are still poor and contradictory (Perroud et al., 2010) (see also Discussion). Further, possible modulators of the association were investigated.

Section snippets

Search strategy

An electronic search of the literature was performed to identify association studies investigating the link between 5-HTTLPR and antidepressant response. PubMed, PsycINFO and ISI Web of Knowledge databases were searched for articles published until November 2010 using any combination of the terms “SERT”, “5-HTT”, “SLC6A4”, “serotonin transporter gene”, “HTTLPR” with both “antidepressant”, “SSRIs”, “SSRI”, “SNRIs”, “SNRI”, “NRI”, “Tricyclic”, “response” and “remission”. References from retrieved

Results

An overview of the selected studies on the association between 5-HTTLPR and antidepressant response/remission is provided in Table 1. With regard to studies on the STAR*D sample, we included in the first step of our analysis both the study by Hu et al. (2007) and Mrazek et al. (2009) one at a time, in order to test the impact on the effect size. In the second step, we included the study by Mrazek et al. (2009), since, unlike Hu et al. (2007), it reported results split for ethnic group. On the

Discussion

The aim of this meta-analysis was to elucidate the influence of 5-HTTLPR on antidepressant efficacy, since the studies published so far reached contradictory findings. We retrieved 33 studies to perform an exploratory analysis and test the impact of 5-HTTLPR on antidepressant efficacy without any a priori hypothesis. We found evidence of association between the l/l genotype and l allele and remission (Supplementary Fig. 1). Thus, we tried to dissect the association in order to identify the

Role of the funding source

This study was institutionally supported.

Contributors

Porcelli S. and Fabbri C. performed the electronic search of the literature and carried out a dataset with study information. They equally contributed to the analysis of data and to the drafting of the review. Serretti A. assisted in the preparation of the manuscript and contributed to the drafting of the discussion.

Conflict of interest

Dr. Serretti is or has been a consultant/speaker for: Abbott, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Pfizer, Sanofi, and Servier.

References (89)

  • C. Minov et al.

    Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

    Neurosci. Lett.

    (2001)
  • C.H. Ng et al.

    Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (2006)
  • G.I. Papakostas et al.

    Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder

    Psychiatry Res.

    (2008)
  • R.H. Perlis et al.

    Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

    Biol. Psychiatry

    (2003)
  • B.G. Pollock et al.

    Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression

    Neuropsychopharmacology

    (2000)
  • J.L. Rausch et al.

    Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

    Biol. Psychiatry

    (2002)
  • F. Reimherr et al.

    Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine

    Psychiatry Res.

    (2010)
  • M.J. Taylor et al.

    Antidepressant response and the serotonin transporter gene-linked polymorphic region

    Biol. Psychiatry

    (2010)
  • E. Walderhaug et al.

    Interactive effects of sex and 5-HTTLPR on mood and impulsivity during tryptophan depletion in healthy people

    Biol. Psychiatry

    (2007)
  • K. Yoshida et al.

    Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients

    Prog. Neuropsychopharmacol. Biol. Psychiatry

    (2002)
  • R. Zanardi et al.

    Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

    Biol. Psychiatry

    (2001)
  • J. Angst

    The prognosis of antidepressive treatments: longitudinal and genetic studies

    Anglo Ger. Med. Rev.

    (1965)
  • B. Arias et al.

    5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study

    J. Clin. Psychopharmacol.

    (2003)
  • A. Baffa et al.

    Norepinephrine and serotonin transporter genes: impact on treatment response in depression

    Neuropsychobiology

    (2010)
  • R.M. Bagby et al.

    Psychosocial and clinical predictors of response to pharmacotherapy for depression

    J. Psychiatry Neurosci.

    (2002)
  • W.L. Baker et al.

    Understanding heterogeneity in meta-analysis: the role of meta-regression

    Int. J. Clin. Pract.

    (2009)
  • B.T. Baune et al.

    Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect?

    Depress Anxiety

    (2008)
  • F. Benedetti et al.

    Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation

    J. Clin. Psychopharmacol.

    (2008)
  • N. Bozina et al.

    Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder

    World J. Biol Psychiatry

    (2008)
  • J.D. Bukh et al.

    Interaction between genetic polymorphisms and stressful life events in first episode depression

    J. Affect. Disord.

    (2009)
  • O. Dogan et al.

    Serotonin transporter gene polymorphisms and sertraline response in major depression patients

    Genet. Test.

    (2008)
  • C. Dong et al.

    Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

    Mol. Psychiatry

    (2009)
  • L.K. Durham et al.

    The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

    Psychopharmacology (Berl)

    (2004)
  • M. Egger et al.

    Meta-analysis: principles and procedures

    BMJ

    (1997)
  • N. Goldman et al.

    The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms

    Depress Anxiety

    (2010)
  • F. Gressier et al.

    5-HTTLPR modulates antidepressant efficacy in depressed women

    Psychiatr. Genet.

    (2009)
  • S. Grigoriadis et al.

    Gender issues in depression

    Ann. Clin. Psychiatry

    (2007)
  • A. Halfin

    Depression: the benefits of early and appropriate treatment

    Am. J. Manag. Care

    (2007)
  • A. Heils et al.

    Allelic variation of human serotonin transporter gene expression

    J. Neurochem.

    (1996)
  • J.P. Higgins et al.

    Measuring inconsistency in meta-analyses

    BMJ

    (2003)
  • H. Higuchi et al.

    No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders

    Psychiatry Clin. Neurosci.

    (2008)
  • C.J. Hong et al.

    Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder

    Pharmacogenomics J.

    (2006)
  • X.Z. Hu et al.

    Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression

    Arch. Gen. Psychiatry

    (2007)
  • P. Huezo-Diaz et al.

    Moderation of antidepressant response by the serotonin transporter gene

    Br. J. Psychiatry

    (2009)
  • Cited by (278)

    • Pharmacogenomics testing: An overview

      2023, Pharmacogenomics: from Discovery to Clinical Implementation
    • Pharmacogenomics in drug discovery and development

      2023, Pharmacogenomics: from Discovery to Clinical Implementation
    View all citing articles on Scopus
    1

    Authors contributed equally to the manuscript.

    View full text